reported: azatyrosin (Krzyzosiak et al., 1992; Kyprianou et al., 1992) , okadaic acid (Sakai et al., 1989) , herbimycin A (Uehara et al., 1989) , tyrosine kinase inhibitors (Umezawa et al., 1991) , trichostatin A (Sugita et al., 1992a) and depudecin (Sugita et al., 1992b) ; most of these have been isolated from micro-organism cultured media.
We have discovered a synthetic low molecular weight compound, a styryl diphenylamin derivative, which induces flat revertants in human fibrosarcoma HT1080 cells derived from naturally occurring tumours. In the initial study we screened derivatives of lobenzarit disodium, an agent used to treat rheumatoid arthritis (Ohsugi et al., 1983) , to study the modulation of cytokine induction. We noticed that a few of the derivatives could direty alter the morphology of certain tumour cell lines which expresed a flat revertant-like phenotype. Among these, HT1080 cells were found to be an appropnate candidate in terms of exhibiting definite alterations in cell morphology. Since we were interested in exploring new compounds that have a stronger ability to alter the morphology of HT1080 cells into the flat revertant, we started to synthesise scores of such derivatives. Finally, we found a novel and potent derivative, RX465, dissimilar to conventional anti-cancer drugs in chemical strucre. We predicted that the styryl diphenylamine derivative would be able to reduce the malignant phenotype of tumour ells, because the cell morphology induced by this compound is closely related to that of the flat revertant, showing reduction of mutant N-ras gene product p21 (p21IN), which par- ticipates in the control of this transformed phenotype as shown in HT1080 cells using a suicide technique (Paterson et al., 1987) .
In The studies described here have shown that a novel styryl diphenylamine derivative, RX-465, reduces the malignant phenotype of human fibrosarcoma HT1080 cells, including features such as rapid rates of proliferation accompanied by cellular piling, high saturation density at confluence, anchorage-independent growth in soft agar and tumorigenicity in nude mice. The revertant cells treated with RX-465 displayed a slower growth rate compared with cells treated with control vehicle, accompanied by morphological alterations of a flattened appearance which closely resembled revertants obtained by Paterson et al. (1987) as selected from HT1080 cells by a suicide technique. It is apparent that the slower growth rate in HT1080 cells treated with RX-465 could not be attributed to anomalous factors such as either acute or delayed cytotoxicity because the reproducibility in their growth rate was observed when the revertant cells were reioculated after achieving confluence. As a consequence of the simple reductions in mutant p2l1, as observed by Paterson et al. (1987) , similar morphological changes in HT1080 cells treated with RX-465 might indcate the possibility of a role for this compound in counteracting neoplastic transformation. Moreover, treatment of HT1080 cells with RX-465 resulted in a lower saturation density and inhibition of anchorage-independent growth in soft agar, both of which characteristics have been associated with reduction of tumour formation in mice, the most crifical phenotypic measure of cell transformation. (Aaronson and Todaro, 1968; Freedman et al., 1974) . In terms of the relationship between the capability of cell transformation in vitro and in vivo, there are some exceptions. Not all revertant cells which show a decrease in saturation density and a complete loss of capacity for anchorage-independent growth, also show a reduction of tumorigenicity in vivo because of phenotypic instability (Haynes and Downing, 1988) . In this context the reduction of the tumorigenicity observed with HT1080 cells treated with RX-465 can be understood to demonstrate that the revertant cells have a stable phenotype which can contribute to the reduction of proliferation in vivo. Instability of the revertant phenotype after elimination of RX-465 was only observed during passage 3 in monolayer culture. This is perhaps because certain unkrnown key factors that are epigenetic components which influence growth regulation are abolished in continuous culture. Also, the frequency of reversion was 96% (1569 out of 1635 cells slcted at random) after 7 days' treatment with 10 pM RX-465 in HT1080 cells, which suggests that a small number of the cells that can resist RX-465 treatment were able to proliferate and dominate culture characterisics after passage 3. Some of the characteristics of maligant tumour cells are cell densityindepenent proliferation, anchorage-independent growth and tumorigenicity in nude mice. A styryl diphenylaine derivative able to diminish these transforming activities could help to elucidate the molecular basis of cell transformation in malignant tumours.
The mechanism by which this styryl diphenylamine derivative reverts the transformed phenotype of human fibrosarcoma HT1080 cells is still unknown. In our initial studies, we speculated on the basis of the study performed by Paterson et al. (1987) that the derivative might reduce cellular concentration of mutant p2l'. However, we found that the alteration to flat cell morphology was observed in three out of seven cancer cell lines which exhibit ras activation, suggesting that RX-465 may not necessarily revert the phenotype of every tumour cell that contains activated ras oncogenes.
Therefore, we speculate that the cellular reversion is rarely attributed to a depletion of ras function, although it is apparent that this phenomenon is not restricted only to HT1080 fibrosarcoma cells. Intrestingly, this compound exerted strong growth inhibitory activity in six out of seven cancer cell lines and had little cytotoxicity in three human normal diploid fibroblast lines. Taken together, our results suggest that RX-465 may have specificity for growth inhibition of tumour cells, including some morphological effects. Next we investigated whether this reversion on the transformed phenotype is associated with tyrosine protein kinase (TPK) activity since RX-465 is similar in chemical structure to TPK inhibitors such as erbstatin, classified with 'styrylbased' inhibitors (Smyth et al., 1993) . However, on direct assay of TPK activity we found no evidence for a relationship between signal tansductions induced by TPK and the reversion by RX-465 (unpublished data). As a consequence, we speculate that RX-465 may play an important role in the counteraction of common cellular events, independent of ras functions among L-929, B16 melanoma and HT1080 fibrosarcoma cells.
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